Article Information
History
- May 11, 2021.
Article Versions
- Version 1 (December 4, 2020 - 15:13).
- You are currently viewing Version 2 of this article (May 11, 2021 - 08:37).
- Version 3 (May 17, 2021 - 15:03).
- Version 4 (June 7, 2021 - 08:41).
- Version 5 (July 2, 2021 - 11:00).
- View Version 6, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kevin Zhang, MD(c)1,*,
- Patricia Beckett, RN2,
- Salaheddin Abouanaser, MD2 and
- Marek Smieja, MD, PhD2,3
- 1Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada
- 2St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada
- 3Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L8S 4L8, Canada
- ↵*Correspondence:
Kevin Zhang, Faculty of Medicine, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, kevink.zhang{at}mail.utoronto.ca, (+1)416-978-6585
Posted May 11, 2021.
Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
